A novel formulation based on 2,3-di(tetradecyloxy)propan-1-amine cationic lipid combined with polysorbate 80 for efficient gene delivery to the retina
- PMID: 24449439
- DOI: 10.1007/s11095-013-1271-5
A novel formulation based on 2,3-di(tetradecyloxy)propan-1-amine cationic lipid combined with polysorbate 80 for efficient gene delivery to the retina
Abstract
Purpose: The aim of the present study was to evaluate the potential application of a novel formulation based on a synthesized cationic lipid 2,3-di(tetradecyloxy)propan-1-amine, combined with polysorbate 80 to deliver the pCMS-EGFP plasmid into the rat retina.
Methods: We elaborated lipoplexes by mixing the formulation containing the cationic lipid and the polysorbate 80 with the plasmid at different cationic lipid/DNA ratios (w/w). Resulted lipoplexes were characterized in terms of size, charge, and capacity to condense, protect and release the DNA. In vitro transfection studies were performed in HEK-293 and ARPE-19 cells. Formulations were also tested in vivo by monitoring the expression of the EGFP after intravitreal and subretinal injections in rat eyes.
Results: At 2/1 cationic lipid/DNA mass ratio, the resulted lipoplexes had 200 nm of hydrodynamic diameter; were positive charged, spherical, protected DNA against enzymatic digestion and transfected efficiently HEK-293 and ARPE-19 cultured cells exhibiting lower cytotoxicity than LipofectamineTM 2000. Subretinal administrations transfected mainly photoreceptors and retinal pigment epithelial cells; whereas intravitreal injections produced a more uniform distribution of transfection through the inner part of the retina.
Conclusions: These results hold great expectations for other gene delivery formulations based on this cationic lipid for retinal gene therapy purposes.
Similar articles
-
A novel cationic niosome formulation for gene delivery to the retina.J Control Release. 2014 Jan 28;174:27-36. doi: 10.1016/j.jconrel.2013.11.004. Epub 2013 Nov 11. J Control Release. 2014. PMID: 24231407
-
The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain.Biomaterials. 2016 Jan;77:267-79. doi: 10.1016/j.biomaterials.2015.11.017. Epub 2015 Nov 14. Biomaterials. 2016. PMID: 26610076
-
Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60.J Control Release. 2017 May 28;254:55-64. doi: 10.1016/j.jconrel.2017.03.386. Epub 2017 Mar 24. J Control Release. 2017. PMID: 28347807
-
Gene delivery to the rat retina by non-viral vectors based on chloroquine-containing cationic niosomes.J Control Release. 2019 Jun 28;304:181-190. doi: 10.1016/j.jconrel.2019.05.010. Epub 2019 May 6. J Control Release. 2019. PMID: 31071372
-
Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration.Int J Pharm. 2018 Oct 25;550(1-2):388-397. doi: 10.1016/j.ijpharm.2018.07.035. Epub 2018 Sep 7. Int J Pharm. 2018. PMID: 30009984
Cited by
-
How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?Int J Mol Sci. 2021 Jul 14;22(14):7545. doi: 10.3390/ijms22147545. Int J Mol Sci. 2021. PMID: 34299164 Free PMC article. Review.
-
Correlation between Biophysical Properties of Niosomes Elaborated with Chloroquine and Different Tensioactives and Their Transfection Efficiency.Pharmaceutics. 2021 Oct 26;13(11):1787. doi: 10.3390/pharmaceutics13111787. Pharmaceutics. 2021. PMID: 34834203 Free PMC article.
-
Cationic Niosomes as Non-Viral Vehicles for Nucleic Acids: Challenges and Opportunities in Gene Delivery.Pharmaceutics. 2019 Jan 22;11(2):50. doi: 10.3390/pharmaceutics11020050. Pharmaceutics. 2019. PMID: 30678296 Free PMC article. Review.
-
Niosome-Based Approach for In Situ Gene Delivery to Retina and Brain Cortex as Immune-Privileged Tissues.Pharmaceutics. 2020 Feb 25;12(3):198. doi: 10.3390/pharmaceutics12030198. Pharmaceutics. 2020. PMID: 32106545 Free PMC article. Review.
-
Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity.Pharmaceuticals (Basel). 2019 Sep 26;12(4):146. doi: 10.3390/ph12040146. Pharmaceuticals (Basel). 2019. PMID: 31561546 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous